DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Sanofi - 2 Gonzalo Fuentes - 2 Ludwig Burger - 2 BOREAS - 1 Tassilo Hummel - 1 Edwina Gibbs - 1 Hudson - 1 drugmaker - 1
Top related locs:
Lyon France Bellevue Paris
Top related orgs:
Sanofi - 2 Polyclonals - 2 REUTERS - 2 Thomson - 2 Food and Drug Administration - 1 Bellevue Asset Management - 1 Barclays - 1 Johnson - 1

Search resuls for: "Polyclonals"


2 mentions found


☆ Sanofi looks to widen Dupixent use to treat 'smoker's lung' after second trial win
  + stars: | 2023-11-27 | by ( Ludwig Burger | ) www.reuters.com   time to read: +2 min
The logo of French drugmaker Sanofi is seen a the Sanofi Genzyme Polyclonals in Lyon, France, September 30, 2023. REUTERS/Gonzalo Fuentes/File photo Acquire Licensing RightsNov 27 (Reuters) - Sanofi (SASY.PA) plans to seek U.S. approval for it best-selling anti-inflammatory drug Dupixent to be used in the treatment of "smoker's lung", also known as COPD, after a second large trial showed significant benefits. The company had embarked on a second trial to bolster the statistical reliability of the read-outs. Details of the second trial would be presented at an as yet undisclosed medical conference, Sanofi added. The company has been discussing with major watchdogs across the world whether the BOREAS results were substantial enough to support a regulatory review and what role the second trial would play in reviews.
Persons: Sanofi, Gonzalo Fuentes, BOREAS, Ludwig Burger, Tassilo Hummel, Edwina Gibbs Organizations: Sanofi, Polyclonals, REUTERS, Food and Drug Administration, Thomson Locations: Lyon, France
☆ Sanofi loses $21 bln in market value after dropping 2025 profit target
  + stars: | 2023-10-27 | by ( Ludwig Burger | ) www.reuters.com   time to read: +6 min
Under a push to spend more on immunology and inflammation drug development, the company abandoned a target for a 32% operating profit margin for 2025 to focus on "long-term profitability". EPS would see a strong rebound in 2025 but not enough to sustain the previous margin target. CONSUMER STAND-ALONECEO Hudson said the core innovative drugs business had improved enough to soon do without the more predictable cash flows from consumer products. The logo of French drugmaker Sanofi is seen a the Sanofi Genzyme Polyclonals in Lyon, France, September 30, 2023. The timing of the potential consumer listing, which Sanofi said would be in the fourth quarter of 2024 or later, would be set to maximize shareholder value.
Persons: Hudson, Sanofi, drugmaker, Paul Hudson, Terence McManus, Johnson, we've, Gonzalo Fuentes, Roche, Dupixent, Ludwig Burger, Sherry Jacob, Phillips, Mark Potter, Sharon Singleton Organizations: Sanofi, Bellevue Asset Management, Reuters, Barclays, Johnson, GSK, Pfizer, Bayer, Polyclonals, REUTERS, Provention, Merck & Co, Thomson Locations: France, Bellevue, Lyon, Paris
0 next >>
Total: 2